Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Kinon Bruce J.; Millen Brian A.; Zhang Lu; McKinzie David L.

首页> 外文期刊>Biological psychiatry >Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

【24h】

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

机译：探索性分析的精神分裂症患者代谢型谷氨酸2/3受体激动剂Pomaglumetad Methionil的目标患者群体。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND: Accumulating evidence indicates that glutamatergic tone in schizophrenia may vary as a function of illness duration or medication history. We conducted an exploratory analysis of the existing clinical trial database of pomaglumetad methionil (pomaglumetad) to demonstrate treatment response in targeted patient populations.

机译：背景：越来越多的证据表明，精神分裂症中的谷氨酸能基调可能随疾病持续时间或用药史而变化。我们对pomaglumetad methionil（pomaglumetad）的现有临床试验数据库进行了探索性分析，以证明目标患者人群的治疗反应。

著录项

来源
《Biological psychiatry》 |2015年第11期|共9页
作者
Kinon Bruce J.; Millen Brian A.; Zhang Lu; McKinzie David L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词
Epigenetic; Glutamate; Pomaglumetad; Risperidone; Schizophrenia; Treatment history;

机译：表观遗传;谷氨酸;Pomaglumetad;利培酮;精神分裂症;治疗史;

相似文献

外文文献
中文文献
专利

1. Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia [J] . Kinon Bruce J., Millen Brian A., Zhang Lu, Biological psychiatry . 2015,第11期

机译：探索性分析的精神分裂症患者代谢型谷氨酸2/3受体激动剂Pomaglumetad Methionil的目标患者群体。
2. Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023) [J] . Annes William F., Long Amanda, Witcher Jennifer W., Journal of pharmaceutical sciences. . 2015,第1期

机译：口服前药Pomaglumetad Methionil（LY2140023）后，系统和全身肽酶对新型代谢型谷氨酸2/3受体激动剂（LY404039）的口服暴露的相对贡献。
3. A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia [J] . StaufferV.L., BayganiS.K., KinonB.J., Journal of clinical psychopharmacology . 2014,第5期

机译：使用电子病历报告的精神分裂症患者的代谢型谷氨酸2/3受体激动剂的短期，多中心，安慰剂对照，随机退出研究
4. Inverse agonists to explore the mechanisms of metabotropic glutamate receptor activity [C] . L. Prezeau, M.L. Parmentier, R Carroll, Fundaci髇 Dr. Antonio Esteve . 2003

机译：反向激动剂探讨代谢谷氨酸受体活性的机制
5. Metabotropic glutamate receptors as targets for antiepileptic drug therapy: A behavioral and electroencephalographic analysis. [D] . Caulder, Erin H. 2013

机译：代谢型谷氨酸受体作为抗癫痫药物治疗的靶标：行为和脑电图分析。
6. A Short-Term Multicenter Placebo-Controlled Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia [O] . Virginia L. Stauffer, Simin K. Baygani, Bruce J. Kinon, -1

机译：短期多中心安慰剂控制的代谢型谷氨酸2/3受体激动剂在精神分裂症患者中使用电子报告患者的短期退出随机研究。
7. Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia [O] . Laura K. Nisenbaum, AnnCatherine M. Downing, Fangyi Zhao, 2016

机译：血清素2a受体sNp rs7330461与精神分裂症患者对pomaglumetad methionil治疗反应的关联
8. Group II Metabotropic Glutamate Receptors as Potential Pharmaceutical Targets for Neurofibroma Formation [R] . Stern, M. 2011

机译：第II组代谢型谷氨酸受体作为神经纤维瘤形成的潜在药物靶标

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

摘要

著录项

相似文献

相关主题

期刊订阅